Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning.

PURPOSE Low-dose-rate brachytherapy using iodine-125 seeds is a highly efficacious treatment for low-risk prostate cancer. We propose a bioeffect model may be used to target an ablative dose to the tumor with a lower, therapeutic dose to low-risk regions to maintain high rates of tumor control with reduced toxicity. We report on the validation of the model and derivation of the optimal cutpoint value of tumor control probability (TCP) that predicts for freedom from biochemical failure. METHODS AND MATERIALS The TCP was calculated from postimplant dosimetry data for 423 prostate cancer patients from three Australian institutions. To apply the model, the prostate was mathematically divided into 12 subsections with tumor characteristics, including a nonuniform distribution of tumor cell density, derived from the literature. RESULTS When TCP values were above and below 0.62, the 5-year freedom from biochemical failure were 93.7% (95% confidence interval [CI], 90.4, 96.4%) and 88.8% (95% confidence interval, 81.3, 94.5%), respectively (p = 0.004). CONCLUSIONS Using postimplant dosimetry data, the TCP model was able to predict for freedom from biochemical failure. The cutpoint value that would be used clinically depends on the selection of the model parameters, but the potential for the model to be used in the optimization of treatment planning is demonstrated.

[1]  Oleg S. Pianykh,et al.  Digital Imaging and Communications in Medicine (DICOM) , 2017, Radiopaedia.org.

[2]  Louis Potters,et al.  Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. , 2007, International journal of radiation oncology, biology, physics.

[3]  C Busch,et al.  Modeling prostate cancer distributions. , 1999, Urology.

[4]  Seong Ki Mun,et al.  Modeling and mapping of prostate cancer , 2000, Comput. Graph..

[5]  Achim Zeileis,et al.  Generalized Maximally Selected Statistics , 2008, Biometrics.

[6]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[7]  W. Butler,et al.  AAPM Recommendations on Dose Prescription and Reporting Methods for Permanent Interstitial Brachytherapy for Prostate Cancer Report of AAPMTask Group , 2009 .

[8]  Berthold Lausen,et al.  Maximally selected rank statistics , 1992 .

[9]  Howard Pai,et al.  Population‐based 10‐year oncologic outcomes after low‐dose‐rate brachytherapy for low‐risk and intermediate‐risk prostate cancer , 2013, Cancer.

[10]  R G Dale,et al.  Dose-rate effects in targeted radiotherapy. , 1996, Physics in medicine and biology.

[11]  John Kurhanewicz,et al.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer , 2012, BJU international.

[12]  L. Anderson,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[13]  J. Sylvester,et al.  Outcomes after prostate brachytherapy are even better than predicted , 2012, Cancer.

[14]  G. Morton.  The best method for dose escalation: Prostate brachytherapy. , 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[15]  Annette Haworth,et al.  Assessment of i-125 prostate implants by tumor bioeffect. , 2004, International journal of radiation oncology, biology, physics.

[16]  S. Zavgorodni,et al.  Modeling dose response in the presence of spatial variations in dose rate. , 2000, Medical physics.

[17]  Ravinder Nath,et al.  AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. , 2009, Medical physics.

[18]  Saint Louis,et al.  American Association of Physicists in Medicine , 2014 .

[19]  S Webb,et al.  A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. , 1993, Physics in medicine and biology.

[20]  Adam P Dicker,et al.  Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group , 2012, BJU international.

[21]  R. Dale.  Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. , 1989, The British journal of radiology.

[22]  Oliver Sartor,et al.  Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. , 2007, The Journal of urology.

[23]  H. Ahmed,et al.  Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study , 2012, The Lancet. Oncology.

[24]  D. Bostwick,et al.  Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. , 2007, Urology.

[25]  Annette Haworth,et al.  Prostate implant evaluation using tumour control probability--the effect of input parameters. , 2004, Physics in medicine and biology.

[26]  D. Grignon,et al.  Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). , 2009, International journal of radiation oncology, biology, physics.

[27]  W. J. Morris,et al.  Point: the relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: is there an elephant in the room? , 2010, Brachytherapy.

[28]  Mark Emberton,et al.  Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer , 2012, BJU international.

[29]  X. Allen Li,et al.  HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .

[30]  Liang Cheng,et al.  Tumor focality does not predict biochemical recurrence after radical prostatectomy in men with clinically localized prostate cancer. , 2011, The Journal of urology.

[31]  D. Greene,et al.  Salvage cryotherapy: is there a role for focal therapy? , 2010, Journal of endourology.

[32]  R. Stock,et al.  (125)I monotherapy using D90 implant doses of 180 Gy or greater. , 2008, International journal of radiation oncology, biology, physics.

[33]  H. Klocker,et al.  Characteristics of prostate cancers detected at low PSA levels , 2004, The Prostate.

[34]  D. Johnston,et al.  Detailed mapping of prostate carcinoma foci , 2000, Cancer.

[35]  Peter T Scardino,et al.  Focal therapy for prostate cancer: analysis by an international panel. , 2008, Urology.

[36]  M. P. Van Gellekom,et al.  How low is the alpha/beta ratio for prostate cancer? , 2003, International journal of radiation oncology, biology, physics.

[37]  J. Williamson,et al.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2003, Medical physics.

[38]  R. DePinho,et al.  Modeling prostate cancer in the mouse. , 2001, Advances in cancer research.